PL2791177T3 - Cząsteczki przeciwciała wiążące trombinę i ich zastosowania - Google Patents

Cząsteczki przeciwciała wiążące trombinę i ich zastosowania

Info

Publication number
PL2791177T3
PL2791177T3 PL12806641T PL12806641T PL2791177T3 PL 2791177 T3 PL2791177 T3 PL 2791177T3 PL 12806641 T PL12806641 T PL 12806641T PL 12806641 T PL12806641 T PL 12806641T PL 2791177 T3 PL2791177 T3 PL 2791177T3
Authority
PL
Poland
Prior art keywords
thrombin
antibody molecules
binding antibody
binding
molecules
Prior art date
Application number
PL12806641T
Other languages
English (en)
Inventor
James Andrew Huntington
Trevor Baglin
Jonathan Langdown
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of PL2791177T3 publication Critical patent/PL2791177T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12806641T 2011-12-14 2012-12-14 Cząsteczki przeciwciała wiążące trombinę i ich zastosowania PL2791177T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1121513.4A GB201121513D0 (en) 2011-12-14 2011-12-14 Thrombin-binding antibody molecules and uses thereof
EP12806641.2A EP2791177B1 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof
PCT/GB2012/053140 WO2013088164A1 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof

Publications (1)

Publication Number Publication Date
PL2791177T3 true PL2791177T3 (pl) 2018-03-30

Family

ID=45560465

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12806641T PL2791177T3 (pl) 2011-12-14 2012-12-14 Cząsteczki przeciwciała wiążące trombinę i ich zastosowania

Country Status (34)

Country Link
US (5) US9518129B2 (pl)
EP (2) EP2791177B1 (pl)
JP (2) JP6216954B2 (pl)
KR (1) KR102114506B1 (pl)
CN (2) CN104053673B (pl)
AU (2) AU2012351858B2 (pl)
BR (1) BR112014014605A2 (pl)
CA (1) CA2856656C (pl)
CO (1) CO7101192A2 (pl)
CY (1) CY1119599T1 (pl)
DK (1) DK2791177T3 (pl)
ES (1) ES2642718T3 (pl)
GB (1) GB201121513D0 (pl)
HK (1) HK1246326A1 (pl)
HR (1) HRP20171775T1 (pl)
HU (1) HUE034793T2 (pl)
IL (1) IL232797B (pl)
LT (1) LT2791177T (pl)
ME (1) ME02901B (pl)
MX (2) MX376876B (pl)
MY (1) MY170980A (pl)
NO (1) NO2791177T3 (pl)
PE (2) PE20190171A1 (pl)
PH (1) PH12014501169B1 (pl)
PL (1) PL2791177T3 (pl)
PT (1) PT2791177T (pl)
RS (1) RS56510B1 (pl)
RU (2) RU2642276C2 (pl)
SG (1) SG11201402560WA (pl)
SI (1) SI2791177T1 (pl)
SM (1) SMT201700580T1 (pl)
UA (1) UA116531C2 (pl)
WO (1) WO2013088164A1 (pl)
ZA (1) ZA201403836B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201310949D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Binding Motif
GB201310948D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Screening methods
CA3013254A1 (en) * 2016-02-05 2017-08-10 Jiangsu Hengrui Medicine Co., Ltd. Thrombin antibody, antigen-binding fragment and pharmaceutical use thereof
CN107043423B (zh) * 2016-02-05 2021-02-26 江苏恒瑞医药股份有限公司 凝血酶抗体、其抗原结合片段及医药用途
WO2018081534A1 (en) * 2016-10-28 2018-05-03 President And Fellows Of Harvard College Assay for exo-site binding molecules
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
WO2020003077A1 (en) * 2018-06-25 2020-01-02 Janssen Pharmaceutica Nv Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504605A (ja) * 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
US5240913A (en) 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
AU7793291A (en) 1990-05-10 1991-11-27 Cetus Corporation Inhibitors of factor xii activation and applications thereof
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5443827A (en) * 1993-05-03 1995-08-22 President And Fellows Of Harvard College Fibrin-targeted inhibitors of thrombin
CA2180140A1 (en) * 1993-12-27 1995-07-06 Jeffrey I. Weitz Methods and compositions for inhibiting thrombogenesis
GB9613718D0 (en) 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
AU5903000A (en) 1999-06-29 2001-01-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel anti-thrombin peptide
CA2378473A1 (en) * 1999-07-23 2001-02-01 The Regents Of The University Of California Modulation of platelet activation
EP1825864A3 (en) * 2000-05-15 2007-09-12 SmithKline Beecham Corporation Antithrombotic agents
WO2002017711A2 (en) 2000-08-31 2002-03-07 Cor Therapeutics, Inc. Therapeutics and diagnostics based on a novel signal transduction system in platelets
EP1411964A4 (en) * 2001-07-06 2006-06-14 Oregon Health Science Universi THE BLOOD GENERATING PEPTIDES AND THEIR USES
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
JP2009508473A (ja) 2005-08-26 2009-03-05 アーケミツクス・コーポレイシヨン 高親和性でトロンビンに結合するアプタマー
AU2007226566A1 (en) 2006-03-15 2007-09-20 Emory University Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor
WO2009154461A1 (en) 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
WO2010033167A2 (en) * 2008-09-18 2010-03-25 Archemix Corp. Anti-thrombin aptamer formulations and methods for use
HRP20250164T1 (hr) 2011-07-22 2025-04-11 Csl Behring Gmbh Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules

Also Published As

Publication number Publication date
US10287363B2 (en) 2019-05-14
JP6705785B2 (ja) 2020-06-03
PE20190171A1 (es) 2019-02-01
WO2013088164A1 (en) 2013-06-20
LT2791177T (lt) 2017-11-27
RU2017144629A3 (pl) 2021-04-05
ME02901B (me) 2018-04-20
EP2791177B1 (en) 2017-09-06
HUE034793T2 (en) 2018-02-28
SMT201700580T1 (it) 2018-01-11
US20210371543A1 (en) 2021-12-02
CN104053673B (zh) 2018-01-12
AU2012351858B2 (en) 2017-10-05
KR20140105556A (ko) 2014-09-01
ZA201403836B (en) 2015-12-23
US20140370008A1 (en) 2014-12-18
NZ625386A (en) 2017-03-31
GB201121513D0 (en) 2012-01-25
US9988463B2 (en) 2018-06-05
PH12014501169A1 (en) 2014-09-08
EP2791177A1 (en) 2014-10-22
NO2791177T3 (pl) 2018-02-03
JP2015501830A (ja) 2015-01-19
CN107936119A (zh) 2018-04-20
CN107936119B (zh) 2021-06-15
EP3275903A1 (en) 2018-01-31
US20190276558A1 (en) 2019-09-12
CA2856656A1 (en) 2013-06-20
US9518129B2 (en) 2016-12-13
SG11201402560WA (en) 2014-06-27
UA116531C2 (uk) 2018-04-10
PH12014501169B1 (en) 2014-09-08
MX376876B (es) 2025-03-07
BR112014014605A2 (pt) 2017-06-13
CY1119599T1 (el) 2018-04-04
SI2791177T1 (en) 2018-03-30
RS56510B1 (sr) 2018-02-28
JP2018039798A (ja) 2018-03-15
IL232797A0 (en) 2014-07-31
RU2642276C2 (ru) 2018-01-24
RU2017144629A (ru) 2019-02-18
US20170066842A1 (en) 2017-03-09
KR102114506B1 (ko) 2020-05-22
DK2791177T3 (en) 2017-12-18
HRP20171775T1 (hr) 2017-12-29
IL232797B (en) 2018-07-31
MX2014007170A (es) 2015-04-17
ES2642718T3 (es) 2017-11-17
MY170980A (en) 2019-09-23
US20180334511A1 (en) 2018-11-22
AU2012351858A1 (en) 2014-06-12
AU2017268655A1 (en) 2017-12-21
CN104053673A (zh) 2014-09-17
CA2856656C (en) 2021-01-19
JP6216954B2 (ja) 2017-10-25
PT2791177T (pt) 2017-11-29
HK1202564A1 (en) 2015-10-02
HK1246326A1 (en) 2018-09-07
PE20141706A1 (es) 2014-11-13
AU2017268655B2 (en) 2019-05-09
CO7101192A2 (es) 2014-10-31
RU2014124985A (ru) 2016-02-10
MX353281B (es) 2018-01-08

Similar Documents

Publication Publication Date Title
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL272831B (en) Meditops and Meditop binding antibodies and their use
ZA202000056B (en) Engineered microbe-targeting molecules and uses thereof
IL259436A (en) Antibodies against 3angptl and their uses
DK2729170T3 (en) Antibody variants and uses thereof
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
ZA201401843B (en) Antibodies against tl1a and uses thereof
IL231846A0 (en) Antibodies against c-met and their uses
IL232778B (en) Antibodies against pd-l1 and uses thereof
ZA201403836B (en) Thrombin-binding antibody molecules and uses thereof
PL3453723T3 (pl) Przeciwciała anty-asic1 i ich zastosowania
GB201219487D0 (en) Anti-S100A4 antibody molecules and their uses
GB201015790D0 (en) Thrombin-binding antibody molecules and uses thereof
GB201117182D0 (en) Anti-notch antibody molecules and uses thereof
GB201208372D0 (en) Antibodies and uses thereof